actbiotechАктуальная биотехнологияTopical biotechnology2304-4691ВГУИТ10.20914/2304-4691-2021-1-157-159actbiotech-3753Research ArticleСтатьиРАЗРАБОТКА И ПОЛУЧЕНИЕ ДНК-ИММУНОГЕНА НА ОСНОВЕ ГЕНОВ SARS-COV-2РябченковаА. А.noemail@neicon.ruЧиракЕ. Р.noemail@neicon.ruЧиракЕ. Л.noemail@neicon.ruКолмаковН. Н.noemail@neicon.ruДуховлиновИ. В.noemail@neicon.ruООО «АТГ Сервис Ген»Russian Federation20212209202101157159Copyright © Рябченкова А.А., Чирак Е.Р., Чирак Е.Л., Колмаков Н.Н., Духовлинов И.В., 20212021Рябченкова А.А., Чирак Е.Р., Чирак Е.Л., Колмаков Н.Н., Духовлинов И.В.Рябченкова А.А., Чирак Е.Р., Чирак Е.Л., Колмаков Н.Н., Духовлинов И.В.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.actbio-vsuet.ru/jour/article/view/3753ReferencesDey, A. (2021) Immunogenic potential of DNA vaccine candidate, ZyCoV-D against SARS-CoV 2 in animal models. Vaccine, 39(30), 4108-4116.Dey, A. (2021) Immunogenic potential of DNA vaccine candidate, ZyCoV-D against SARS-CoV 2 in animal models. Vaccine, 39(30), 4108-4116.Dhanda, S.K. (2018) Prediction of HLA CD4 immunogenicity in human populations. Front. Immunol., 9, 1369.Dhanda, S.K. (2018) Prediction of HLA CD4 immunogenicity in human populations. Front. Immunol., 9, 1369.Dukhovlinov, I.V., Chirak, E.L., Kolmakov, N.N., Fedorova, E.A. and Alekseev, A.V., (2020) Pat. of the Russian Federation № 2747762, PCT/RU2020/000257 appl. 5.04.2020Dukhovlinov, I.V., Chirak, E.L., Kolmakov, N.N., Fedorova, E.A. and Alekseev, A.V., (2020) Pat. of the Russian Federation № 2747762, PCT/RU2020/000257 appl. 5.04.2020He, Q. (2004) Development of a Western Blot Assay for Detection of Antibodies against Coronavirus Causing Severe Acute Respiratory Syndrome. Clin. Diagn. Lab. Immunol., 11(2), 417-422.He, Q. (2004) Development of a Western Blot Assay for Detection of Antibodies against Coronavirus Causing Severe Acute Respiratory Syndrome. Clin. Diagn. Lab. Immunol., 11(2), 417-422.Lee, J. (2018) Engineering DNA vaccines against infectious diseases. Acta Biomater., 80, 31-47.Lee, J. (2018) Engineering DNA vaccines against infectious diseases. Acta Biomater., 80, 31-47.Momin, Т. (2021) Safety and Immunogenicity of a DNA SARS-CoV 2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India. EClinicalMedicine, 38.Momin, Т. (2021) Safety and Immunogenicity of a DNA SARS-CoV 2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India. EClinicalMedicine, 38.Rodrigues, João P.G.L.M. (2020) Insights on cross-species transmission of SARS-CoV 2 from structural modeling. PLoS Comput Biol., 16(12).Rodrigues, João P.G.L.M. (2020) Insights on cross-species transmission of SARS-CoV 2 from structural modeling. PLoS Comput Biol., 16(12).Vojdania, A., Kharrazianb, D. (2020) Potential antigenic cross-reactivity between SARS-CoV 2 and human tissue with a possible link to an increase in autoimmune diseases. Clinical Immunology, 217, 1-2.Vojdania, A., Kharrazianb, D. (2020) Potential antigenic cross-reactivity between SARS-CoV 2 and human tissue with a possible link to an increase in autoimmune diseases. Clinical Immunology, 217, 1-2.Williams, J.A. (2010) Generic plasmid DNA production platform incorporating low metabolic burden seed-stock and fed-batch fermentation processes. Biotechnol Bioeng., 103(6), 1129-1143.Williams, J.A. (2010) Generic plasmid DNA production platform incorporating low metabolic burden seed-stock and fed-batch fermentation processes. Biotechnol Bioeng., 103(6), 1129-1143.Zhao, J. (2020) Antibody responses to SARS-CoV 2 in patients of novel Antibody responses to SARS-CoV 2 in patients of novel coronavirus disease 2019. Clin. Infect. Dis, 71(16), 2027-2034.Zhao, J. (2020) Antibody responses to SARS-CoV 2 in patients of novel Antibody responses to SARS-CoV 2 in patients of novel coronavirus disease 2019. Clin. Infect. Dis, 71(16), 2027-2034.
The authors declare that there are no conflicts of interest present.